Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 14/20 | 1.00 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.68 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037851 | 0.84 | FOLH1 (0.72) | FOLH1NAALAD2GRM3 | |
| SCHEMBL7608702 | 0.84 | FOLH1 (0.72) | FOLH1NAALAD2GRM3 | |
| SCHEMBL108166 | 0.82 | FOLH1 (0.76) | FOLH1NAALAD2GRM3 | |
| SCHEMBL16528808 | 0.81 | FOLH1 (1.00) | FOLH1NAALAD2GRM3 | |
| SCHEMBL9461503 | 0.81 | FOLH1 (0.68) | FOLH1NAALAD2GRM3 | |
| SCHEMBL383173 | 0.81 | FOLH1 (1.00) | FOLH1NAALAD2GRM3 | |
| SCHEMBL16528703 | 0.81 | FOLH1 (1.00) | FOLH1NAALAD2GRM3 | |
| SCHEMBL8048478 | 0.80 | FOLH1 (0.66) | FOLH1NAALAD2GRM3 | |
| SCHEMBL7605302 | 0.80 | FOLH1 (0.66) | FOLH1NAALAD2GRM3 | |
| SCHEMBL13726298 | 0.79 | FOLH1 (0.73) | FOLH1NAALAD2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | PIRAMAL IMAGING SA (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | PIRAMAL IMAGING SA (CH) | 2012-12-27 | — | — | US | disclosed |
| WO-2011073286-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-23 | — | — | WO | disclosed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, ACP3 | FOLH1 2/4885NAALAD2 123/4885GRM3 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.